SOLICITATION NOTICE
B -- Affymetrix GeneChip Exon Array
- Notice Date
- 3/15/2011
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HL)-2011-110-DDC
- Archive Date
- 4/5/2011
- Point of Contact
- Deborah - Coulter, Phone: (301) 435-0368
- E-Mail Address
-
dc143b@nih.gov
(dc143b@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, for the Framingham Heart Study, intends to award a purchase order on a Brand name basis for the purchase of Affymetrix GeneChip Exon Array. The reference number: NHLBI-CSB-(HL)-2011-110-DDC. The Government requires the Brand name only Product #901087, Affymetrix GeneChip Human Gene 1.0ST Arrays; quantity 10 boxes consist of 30 to a box. Background: Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. The objective of the Framingham Heart Study is to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The Framingham Heart Study continues to make important scientific contributions by enhancing its research capabilities and capitalizing on its inherent resources. The SABRe Initiative is a state-of-the-art research enterprise to advance personalized medicine through biomarker discovery and validation. This project holds great promise for identifying mechanisms of disease and promoting the development of new diagnostics and therapeutics for diseases of high impact. The specific aims for SABRe CVD are as follows: 1. To identify the biomarker signatures of atherosclerosis as determined by: a) aortic and coronary calcification on CT (data available in 3500 people), b) aortic plaque burden by MRI (n=2000), c) carotid intimal-medial thickness by ultrasound (n=3500), d) clinical atherosclerotic CVD (n=500), and e) the dynamic balance between arterial calcification and bone demineralization (n=3500). 2. To identify the biomarker signatures of metabolic risk factors related to cardiovascular risk: a) systolic and diastolic blood pressure (n=7000), b) body mass index (n=7000) and visceral adiposity by CT (n=3500), c) dyslipidemia (lipid levels, n=7000), and d) impaired fasting glucose, diabetes, and insulin resistance (glucose and insulin levels, n=7000). 3. To identify genomic convergence (convergence of signals from genetic variation and gene expression) with SABRe biomarker levels and clinical traits and diseases. The SABRe CVD Initiative Project-3 will conduct gene expression profiling of WBC derived RNA to characterize the genomic signatures of atherosclerosis and metabolic syndrome in 5000-7000 FHS participants (lab work to take place at NHLBI Core Microarray Lab). This process uses the Affymetrix GeneChip Human Gene 1.0 ST Arrays for the gene expression analysis. Brand name determination is based on the following: The Affymetrix GeneChip® is sold only through Affymetrix, or, in certain territories outside of the U.S., through an authorized distributor. The system is covered by patents as listed below, and must be utilized in total to be effective. •Affymetrix high-density probe arrays offer information densities as high as 10 6 per cm 2 and as low as 50 per cm 2. This feature is unique to Affymetrix and covered by patents, USPN 5,445,934, 5,744,305 and others. •Affymetrix photolithography manufacturing technology enables consistent reproduction of array designs and reduces variation inherent in less sophisticated array manufacturing technologies. This feature is unique to Affymetrix and covered by patents USPN 5,424186 and 5,510,270 and others. •The GeneChip Probe Arrays contain a fixed volume reaction chamber, which provides for automated and consistent hybridization of samples to the array. The cartridge housing the probe array is unique to Affymetrix and covered by patents, USPN 5,945,334 and 6,140,044. Features unique to GeneChip Probe Array: •Each GeneChip Probe Array contains over 1,300,000 unique 25-mer probes. •Feature size of each unique probe is 11 micron and contains a million copies of the same sequence. •At least one probe set comprised of 11 unique, perfect match 25-mer probes and 11 unique, mismatch probes interrogates the presence of a transcript. •Each perfect match probe has a mismatch probe containing a single homodimeric base change at position number 13. •Detection sensitivity: 1 transcript in 100,000 in a complex background •Use of the following controls on the probe array: Hybridization controls (bioB, bioC, bioD, and cre), PolyA Controls (dap, lys, phe, thr), Normalization Controls (100 transcript set), and House Keeping genes (actin and GAPDH) The item requested in this purchase includes the Exon gene chips and hyb/wash buffer. The NHLBI core currently operates the Affymetrix high throughput GeneChip Array Station (GCAS) which can produce up to 192 sample outputs which would correspond to 192 individual GeneChip on a regular basis. There is no other company that manufactures these gene chips. These are the only chips that are suitable for the existing Affymetrix platform operated in the core facility. The Exon microarray chip, manufactured by Affymetrix, requires additional reagents and internal and external controls in order to achieve good experimental results. In order to maintain a high standard of quality and reproducibility of experiments while increasing data output, the reagents manufactured by Affymetrix is of critical importance. The delivery point is the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), 73 Mt. Wayte Avenue, Suite 2, Framingham, MA 01702. The notice of intent is not a request for competitive proposals. Only one responsible source and no other supplies or services will satisfy agency requirements. Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology with size standard of 500 employees; the small business set-aside does apply for this requirement. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-48 (January 31, 2011). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by March 21, 2011, 7:30 am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-CSB-(HL)-2011-110-DDC, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, Procurement Branch, 6701 Rockledge Drive, Suite 6042, Bethesda, Maryland 20892-7902, Attention: Deborah Coulter. Response may be submitted electronically to coulterd@nhlbi.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HL)-2011-110-DDC/listing.html)
- Place of Performance
- Address: NIH, Framingham, Massachusetts, 01702, United States
- Zip Code: 01702
- Zip Code: 01702
- Record
- SN02401433-W 20110317/110315235138-0d5e0c5b273b0c4b1bdcfa712cf4258d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |